Anjli Kukreja

Title: The Innovative Contributions of Anjli Kukreja

Introduction

Anjli Kukreja is a prominent inventor based in Fairfield, CT, USA. With a strong focus on medical innovation, she has significantly contributed to the understanding and treatment of atypical hemolytic uremic syndrome (aHUS).

Latest Patents

Kukreja holds three patents, including her latest groundbreaking work on biomarker proteins associated with atypical hemolytic uremic syndrome (aHUS). This patent disclosure provides crucial information about biomarker proteins, where changes in concentration or activity levels are linked to aHUS. Additionally, the document describes compositions and methods designed to assess the concentration and activity of these biomarker proteins in biological fluids. These methods are instrumental in evaluating the risk of developing aHUS, diagnosing patients, monitoring disease progression, and optimizing treatment responses when using complement inhibitors.

Career Highlights

Anjli Kukreja is currently associated with Alexion Pharmaceuticals, Inc., a leading company in the biopharmaceutical industry. Her research and developments are fundamental to improving healthcare outcomes for patients suffering from rare diseases.

Collaborations

Kukreja has collaborated with notable colleagues such as Susan Faas McKnight and Roxanne Cofiell, contributing to a team dedicated to advancing medical research and therapeutic options for patients with aHUS.

Conclusion

Anjli Kukreja's innovative work in the field of biomarker proteins for aHUS reflects her commitment to scientific advancement and patient care. Her patents and collaborations demonstrate the impact of focused research on understanding complex medical conditions. The strides she has made at Alexion Pharmaceuticals, Inc. underline the importance of innovation in the treatment of rare diseases.